ATE260299T1 - Entwurf hormonartiger antikörper mit agonistischen und antagonistischen eigenschaften - Google Patents

Entwurf hormonartiger antikörper mit agonistischen und antagonistischen eigenschaften

Info

Publication number
ATE260299T1
ATE260299T1 AT96939791T AT96939791T ATE260299T1 AT E260299 T1 ATE260299 T1 AT E260299T1 AT 96939791 T AT96939791 T AT 96939791T AT 96939791 T AT96939791 T AT 96939791T AT E260299 T1 ATE260299 T1 AT E260299T1
Authority
AT
Austria
Prior art keywords
antibodies
agonist
hormone
design
antagonist properties
Prior art date
Application number
AT96939791T
Other languages
English (en)
Inventor
H Uri Saragovi
Lynne Lesauter
Original Assignee
Univ Mcgill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Mcgill filed Critical Univ Mcgill
Application granted granted Critical
Publication of ATE260299T1 publication Critical patent/ATE260299T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT96939791T 1995-12-08 1996-12-06 Entwurf hormonartiger antikörper mit agonistischen und antagonistischen eigenschaften ATE260299T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9525180.7A GB9525180D0 (en) 1995-12-08 1995-12-08 Design of hormone-like antibodies with agonistic and antagonistic fuctions
PCT/CA1996/000815 WO1997021732A1 (en) 1995-12-08 1996-12-06 Design of hormone-like antibodies with agonistic and antagonistic functions

Publications (1)

Publication Number Publication Date
ATE260299T1 true ATE260299T1 (de) 2004-03-15

Family

ID=10785168

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96939791T ATE260299T1 (de) 1995-12-08 1996-12-06 Entwurf hormonartiger antikörper mit agonistischen und antagonistischen eigenschaften

Country Status (7)

Country Link
US (1) US6610500B1 (de)
EP (1) EP0869976B1 (de)
AT (1) ATE260299T1 (de)
AU (1) AU7689496A (de)
DE (1) DE69631686T2 (de)
GB (1) GB9525180D0 (de)
WO (1) WO1997021732A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2212315A1 (en) * 1997-08-05 1999-02-05 Mcgill University Pharmaceutical composition with neurotrophic-like biological activity
FR2776661B1 (fr) * 1998-03-26 2002-04-05 Centre Nat Rech Scient Polypeptide immunoreactif du recepteur trka du ngf et utilisations
GB9807781D0 (en) * 1998-04-09 1998-06-10 Univ Bristol Therapeutic agent
US6365154B1 (en) * 1998-09-28 2002-04-02 Smithkline Beecham Corporation Tie2 agonist antibodies
ATE406907T1 (de) * 1998-10-28 2008-09-15 Cornell Res Foundation Inc Methoden zur regulierung der angiogenese und vaskuläre integrität mittels trk rezeptor liganden bdnf, nt-3 und nt-4
US20040120891A1 (en) 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
US6652864B1 (en) 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells
IT1306704B1 (it) 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
FR2807660A1 (fr) * 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
IL153375A0 (en) * 2000-06-22 2003-07-06 Genentech Inc Agonist anti-trk-c monoclonal antibodies
EP1343531A2 (de) * 2000-12-21 2003-09-17 McGILL UNIVERSITY Konjugate von antikörpern und antikrebsmitteln
US8034904B2 (en) * 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
EP1556083B1 (de) 2002-10-08 2011-02-02 Rinat Neuroscience Corp. Verfahren zur behandlung von postoperativen schmerzen durch verabreichung eines antikörpers gegen nervenwachstumsfaktor und diesen enthaltende zusammensetzungen
US7255860B2 (en) 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
EP2270048B1 (de) 2002-12-24 2015-11-11 Rinat Neuroscience Corp. Anti-NGF Antikörper und Verfahren zu ihrer Verwendung
KR20050111598A (ko) 2003-02-19 2005-11-25 리나트 뉴로사이언스 코퍼레이션 신경 성장 인자 길항제 및 ｎｓａｉｄ를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물
PL2248899T3 (pl) 2003-03-19 2015-10-30 Biogen Ma Inc Białko wiążące receptor nogo
EP1500399A1 (de) * 2003-07-24 2005-01-26 Institut Pasteur Aktive und passive Immunisierung gegen pro-apoptotischen Neurotrophinen zur Behandlung oder Vorbeugung von neurologischen Krankheiten
AU2005243247B2 (en) 2004-04-07 2012-03-01 Regents Of The University Of Minnesota Methods for treating bone cancer pain by administering a nerve growth factor antagonist
KR101239542B1 (ko) 2004-06-24 2013-03-07 바이오겐 아이덱 엠에이 인코포레이티드 탈수초화를 수반하는 병의 치료
ITRM20050332A1 (it) * 2005-06-24 2006-12-25 Lay Line Genomics Spa Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore.
CA2902070A1 (en) 2005-07-08 2007-01-18 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
WO2008013782A2 (en) 2006-07-24 2008-01-31 Biogen Idec Ma Inc. Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of sp35 or trka antagonists
AU2009211340B2 (en) 2008-02-04 2013-09-12 Lay Line Genomics S.P.A. Anti-TrkA antibodies and derivatives thereof
JP2011527572A (ja) 2008-07-09 2011-11-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｌｉｎｇｏ抗体または断片を含む組成物
WO2012024650A2 (en) 2010-08-19 2012-02-23 Abbott Laboratories Anti-ngf antibodies and their use
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
NZ611076A (en) 2010-12-01 2015-09-25 Alderbio Holdings Llc Anti-ngf compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
MX381731B (es) 2012-05-14 2025-03-13 Biogen Ma Inc Antagonistas de proteina que interactua con el receptor nogo 2 que contiene repeticion rica en leucina y dominio de inmunoglobulina (lingo-2) para el tratamiento de afecciones que involucran neuronas motoras.
JP6629069B2 (ja) 2012-06-06 2020-01-15 ゾエティス・エルエルシー イヌ化抗ｎｇｆ抗体およびその方法
EP2674439B1 (de) 2012-06-13 2017-02-01 Rottapharm Biotech S.r.l. Ant-TrkA-Antikörper, Derivate und Verwendungen damit
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用
AR114110A1 (es) 2018-02-28 2020-07-22 Lilly Co Eli Anticuerpo anti-trka
MX2020009526A (es) 2018-03-12 2020-10-28 Zoetis Services Llc Anticuerpos anti-ngf y metodos de estos.
MX2021000644A (es) 2018-07-18 2021-08-19 Manzanita Pharmaceuticals Inc Conjugados para suministrar un agente contra el cancer a las celulas nerviosas, metodos de uso y metodos para la elaboracion de los mismos.
JP2025503539A (ja) * 2021-12-28 2025-02-04 ４ビー テクノロジーズ（スーヂョウ） リミテッド ＴｒｋＡ抗体とその応用
EP4716738A1 (de) * 2023-05-23 2026-04-01 4B Technologies (Shanghai) Co., Ltd Trka-antikörper und verwendung davon
US20250122291A1 (en) 2023-10-13 2025-04-17 Cephalon Llc Anti-trka antibodies and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3909799A1 (de) 1989-03-24 1990-09-27 Behringwerke Ag Monoklonale antikoerper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung
EP0471205A1 (de) * 1990-08-15 1992-02-19 E.R. SQUIBB & SONS, INC. Monoklonale Antikörper, die an TRK Proto-Onkogenproteinen binden
US5753225A (en) * 1993-12-03 1998-05-19 The Regents Of The University Of California Antibodies that mimic actions of neurotrophins

Also Published As

Publication number Publication date
EP0869976B1 (de) 2004-02-25
DE69631686T2 (de) 2004-12-02
WO1997021732A1 (en) 1997-06-19
AU7689496A (en) 1997-07-03
EP0869976A1 (de) 1998-10-14
DE69631686D1 (de) 2004-04-01
US6610500B1 (en) 2003-08-26
GB9525180D0 (en) 1996-02-07

Similar Documents

Publication Publication Date Title
DE69631686D1 (de) Entwurf hormonartiger antikörper mit agonistischen und antagonistischen eigenschaften
PT800519E (pt) Compostos moduladores de receptores de esteroides e metodos
EA200100822A1 (ru) Baff, относящиеся к нему блокирующие агенты и их применение в стимуляции и ингибировании b-клеток и иммуноглобулинов в иммунных реакциях
TR200102733T2 (tr) IL-18 kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri
PL332034A1 (en) Monoclonal antibodies against extracellular domain of human vegf (kdr) receptor
ATE348882T1 (de) Humanisierte monoklonale integrin antikörper
MX9704640A (es) Compuesto moduladores de los receptores de los esteroides y metodos para su preparacion.
PL374587A1 (en) Pharmaceutical compositions directed to erb-b1 receptors
PT1648925E (pt) Agentes de imagiologia peptídicos bicíclicos
GEP20084484B (en) Antibodies to insulin-like growth factor i receptor
WO2003016466A3 (en) ANTI-Aβ ANTIBODIES
PT842273E (pt) Ligando de receptor vegf-c
WO2002092635A3 (en) Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens
CA2355976A1 (en) Vascular endothelial cell growth factor antagonists and uses thereof
ZA200108285B (en) Antibody compositions and methods for cancer treatment by selectively inhibiting VEGF.
WO2004108766A3 (en) Anti-hgf-r antibodies and their use
BRPI0414513A (pt) kid3 e anticorpos de kid3 que se ligam a ele
CO6230996A2 (es) Anticuerpos antagonistas anti-notch3 y su uso en la prevencion y el tratamiento de enfermedades relacionadas con el receptor notch3
ATE244571T1 (de) Inhibitorische immunglobulin-polypeptide gegen den pdgf beta-rezeptor
EP1433792A8 (de) Menschlische-rezeptor Proteine; verwandte Reagenzien und Methoden
ATE235551T1 (de) Ligand (tie ligand-4) vom tie-2 rezeptor und dessen verwendungen
EE9900146A (et) Lahustuvad lümfotoksiin-ß retseptorid, lümfotoksiini retseptori vastased antikehad ja lümfotoksiini ligandi vastased antikehad terapeutiliste agensitena immunoloogiliste haiguste raviks
WO1999046379A3 (en) Human receptor proteins; related reagents and methods
NZ515382A (en) OX2 receptor homologs
WO2002022658A3 (en) Muteins of the cgrp 1-7 peptide fragment and use thereof as nicotinic neuronal receptor enhancers

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties